Target Name: USP21
NCBI ID: G27005
Review Report on USP21 Target / Biomarker Content of Review Report on USP21 Target / Biomarker
USP21
Other Name(s): Ubiquitin specific peptidase 21, transcript variant 1 | ubiquitin specific protease 21 | UBP21_HUMAN | USP21 variant 1 | ubiquitin-specific protease 16 | Deubiquitinating enzyme 21 | Ubiquitin carboxyl-terminal hydrolase 21 | USP16 | ubiquitin thiolesterase 21 | ubiquitin specific peptidase 21 | ubiquitin-specific processing protease 21 | Ubiquitin thioesterase 21 | USP23 | deubiquitinating enzyme 21 | Ubiquitin specific protease 21 | ubiquitin thioesterase 21 | Ubiquitin carboxyl-terminal hydrolase 21 (isoform c) | NEDD8-specific protease | Ubiquitin thiolesterase 21 | Ubiquitin-specific-processing protease 21

USP21: A Potential Drug Target and Biomarker for Ubiquitin Specific Peptidase 21

Ubiquitin specific peptidase 21 (USP21) is a protein that plays a crucial role in the regulation of protein degradation in the cell. It is a member of the ubiquitin family of proteins and is involved in the degradation of a wide variety of proteins, including proteins that are involved in cell signaling, DNA damage repair, and inflammation. USP21 has been shown to play a key role in the regulation of the degradation of the protein Parkin, which is associated with a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

Despite the importance of USP21 in cellular regulation, much remains unknown about its functions and the mechanisms that govern its activity. In this article, we will explore the potential drug target and biomarker properties of USP21, with a focus on its role in the regulation of protein degradation and its potential as a therapeutic target.

The Potential Drug Target Property of USP21

The ability of USP21 to serve as a drug target is an attractive feature, given its involvement in the regulation of protein degradation and its potential to contribute to the development of a variety of diseases. One of the key reasons for the potential drug target property of USP21 is its unique structure and biology. USP21 is a monoclonal antibody, which means that it is produced by a single cell and has a single amino acid sequence. This allows for efficient production of USP21 in the laboratory and makes it a good candidate for use as a therapeutic agent.

In addition to its unique structure, USP21 has been shown to have a variety of unique biological properties that make it an attractive drug target. For example, USP21 has been shown to be involved in the regulation of protein degradation, which is a critical process for the control of cellular homeostasis. This suggests that USP21 may play a key role in the development of diseases that are characterized by the accumulation of damaged or dysfunctional proteins.

Another potential drug target property of USP21 is its ability to interact with other proteins, including the transcription factor nuclear factor E2 (NF-E2). This interaction between USP21 and NF-E2 suggests that USP21 may play a role in the regulation of gene expression and may be a potential target for drugs that are designed to modulate gene function.

The Potential Biomarker Property of USP21

In addition to its potential as a drug target, USP21 may also serve as a biomarker for a variety of diseases. One of the key reasons for the potential biomarker property of USP21 is its involvement in the regulation of protein degradation, which is a critical process for the control of cellular homeostasis. This suggests that USP21 may be involved in the regulation of a variety of cellular processes that are critical for overall health and that may be affected by a variety of diseases.

For example, USP21 has been shown to be involved in the regulation of the degradation of the protein Parkin, which is associated with a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. The degradation of Parkin is a process that is regulated by USP21, and studies have shown that USP21 plays a key role in the regulation of Parkin degradation. This suggests that USP21 may be an attractive biomarker for diseases associated with the accumulation of Parkin or other proteins that are involved in the regulation of cellular processes.

Another potential use of USP21 as a biomarker is its ability to be used as a marker for the

Protein Name: Ubiquitin Specific Peptidase 21

Functions: Deubiquitinates histone H2A, a specific tag for epigenetic transcriptional repression, thereby acting as a coactivator. Deubiquitination of histone H2A releaves the repression of di- and trimethylation of histone H3 at 'Lys-4', resulting in regulation of transcriptional initiation. Regulates gene expression via histone H2A deubiquitination (By similarity). Also capable of removing NEDD8 from NEDD8 conjugates but has no effect on Sentrin-1 conjugates (PubMed:10799498). Deubiquitinates BAZ2A/TIP5 leading to its stabilization (PubMed:26100909)

The "USP21 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about USP21 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

USP22 | USP24 | USP25 | USP26 | USP27X | USP27X-DT | USP28 | USP29 | USP3 | USP3-AS1 | USP30 | USP30-AS1 | USP31 | USP32 | USP32P1 | USP32P2 | USP32P3 | USP33 | USP34 | USP35 | USP36 | USP37 | USP38 | USP39 | USP4 | USP40 | USP41 | USP42 | USP43 | USP44 | USP45 | USP46 | USP46-DT | USP47 | USP48 | USP49 | USP5 | USP50 | USP51 | USP53 | USP54 | USP6 | USP6NL | USP6NL intronic transcript 1 (non-protein coding), transcript variant 1 | USP7 | USP8 | USP8P1 | USP9X | USP9Y | USPL1 | UST | UTF1 | UTP11 | UTP14A | UTP14C | UTP15 | UTP18 | UTP20 | UTP23 | UTP25 | UTP3 | UTP4 | UTP6 | UTRN | UTS2 | UTS2B | UTS2R | UTY | UVRAG | UVSSA | UXS1 | UXT | UXT-AS1 | VAC14 | Vacuolar H+ ATPase | VAMP1 | VAMP2 | VAMP3 | VAMP4 | VAMP5 | VAMP7 | VAMP8 | VANGL1 | VANGL2 | VAPA | VAPB | VARS1 | VARS2 | Vascular endothelial growth factor receptor (VEGFR) | Vascular endothelial growth factors (VEGF) | VASH1 | VASH1-AS1 | VASH2 | VASN | Vasoactive intestinal polypeptide receptor (VIP-R) | Vasohibin | Vasopressin Receptor | Vasopressin V1 Receptor | VASP | VAT1